Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M405100200 on July 21, 2004

J. Biol. Chem., Vol. 279, Issue 39, 40807-40818, September 24, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/39/40807    most recent
M405100200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, K.
Right arrow Articles by Sobue, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, K.
Right arrow Articles by Sobue, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Insulin Receptor Substrate-1/SHP-2 Interaction, a Phenotype-dependent Switching Machinery of Insulin-like Growth Factor-I Signaling in Vascular Smooth Muscle Cells*

Ken'ichiro Hayashi, Katsushi Shibata, Tsuyoshi Morita, Kazuhiro Iwasaki, Masahiro Watanabe, and Kenji Sobue{ddagger}

From the Department of Neuroscience (D13), Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka 565-0871, Japan

Received for publication, May 7, 2004 , and in revised form, July 7, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Insulin-like growth factor-I (IGF-I) plays a role in mutually exclusive processes such as proliferation and differentiation in a variety of cell types. IGF-I is a potent mitogen and motogen for dedifferentiated vascular smooth muscle cells (VSMCs) in vivo and in vitro. However, in differentiated VSMCs, IGF-I is only required for maintaining the differentiated phenotype. Here we investigated the VSMC phenotype-dependent signaling and biological processes triggered by IGF-I. In differentiated VSMCs, IGF-I activated a protein-tyrosine phosphatase, SHP-2, recruited by insulin receptor substrate-1 (IRS-1). The activated SHP-2 then dephosphorylated IRS-1 Tyr(P)-895, resulting in blockade of the pathways from IRS-1/Grb2/Sos to the ERK and p38 MAPK. Conversely, such negative regulation was silent in dedifferentiated VSMCs, where IGF-I activated both MAPKs via IRS-1/Grb2/Sos interaction-linked Ras activation, leading to proliferation and migration. Thus, our present results demonstrate that the IRS-1/SHP-2 interaction acts as a switch controlling VSMC phenotype-dependent IGF-I-induced signaling pathways and biological processes, and this mechanism is likely to be applicable to other cells.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The insulin-like growth factors (IGFs)1 are involved in a variety of biological processes regulating cell proliferation, migration, survival, size control, and differentiation (1, 2). IGFs activate the IGF-I receptor (IGF-IR) tyrosine kinase, resulting in the tyrosine phosphorylation of downstream signaling molecules and/or direct interaction with them (1). The major targets of IGF-IR are three adaptor proteins: IRS-1, Shc, and Gab1. IRS-1, an important substrate for both the insulin receptor and IGF-IR, contains multiple tyrosine phosphorylation sites that recognize Src homology 2 domain-containing signaling molecules, such as Grb2, Nck, the p85 subunit of phosphoinositide 3-kinase (p85 PI3K), and SHP-2 (1). Of these, the binding of Grb2 associated with Sos to tyrosine-phosphorylated IRS-1 activates Ras, which switches on the Raf-1/mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-regulated kinase (ERK) cascade (3). The ligand-engaged IGF-IR triggers another pathway involving PI3K. The interaction between tyrosine-phosphorylated IGF-IR{beta} or insulin receptor substrate-1 (IRS-1) and p85 PI3K activates PI3K and its downstream molecules, protein kinase B (PKB(Akt)) and p70S6K (4). Shc, an Src homology 2 domain-containing substrate for receptor tyrosine kinases, interacts directly with IGF-IR (5). After tyrosine phosphorylation of Shc, it recruits the Grb2-Sos complex and activates the Ras/Raf-1/MEK/ERK axis (3). Gab1 functions as an adaptor protein downstream of receptor tyrosine kinases including IGF-IR (6). Tyrosine-phosphorylated Gab1 interacts with Grb2, p85 PI3K, and SHP-2 (7). Thus, the cross-talk among IGF-induced signaling pathways is critical for regulating the variety of biological processes described above.

Recent studies (8) have demonstrated the involvement of IGF-induced signals in the mutually exclusive processes of cell proliferation and differentiation. For instance, pharmacological study showed that although the MAPK pathway induced by IGF-I is involved in the mitogenic response of myoblasts, the PI3K/p70S6K pathway is critical for myogenic differentiation. In hematopoietic cells, IGF-I signaling via IRS-1 plays a role in proliferation and via Shc in differentiation (9). In 3T3-L1 preadipocytes, the IGF-I-induced tyrosine phosphorylation of Shc, Shc-Grb2 complex formation, and ERK activation is observed in proliferating, but not differentiating, cells (10). In osteoblasts, IGF-IR-mediated signals via the PI3K, ERK, and p38 MAPK pathways are all involved in differentiation (11). Thus, the downstream pathways of IGF-I signaling seem to depend on the cellular context. IGF-I is also a potent mitogen and motogen for vascular smooth muscle cells (VSMCs) in vivo and in vitro (12, 13); disruption of the IGF-I/IGF-IR interaction by a neutralizing anti-IGF-IR antibody (14) and suppression of IGF-IR expression by antisense oligonucleotides (15) and transcripts (16) inhibit IGF-I-induced VSMC proliferation and migration in culture. Targeted overexpression of IGF-I in arteries in vivo (17) and infusion of IGF-I into the circulatory system (18) have been shown to accelerate neointimal formation after vascular injury. On the other hand, we recently reported a primary culture system of VSMCs that exhibit a differentiated phenotype, in which isolated VSMCs are cultured on laminin under IGF-I-stimulated conditions (19, 20). By using this culture system, we demonstrated that IGF-I is critically involved in maintaining the differentiated phenotype via the PI3K/PKB(Akt) pathway and that the coordinated activation of ERK and p38 MAPK triggered by other growth factors induces VSMC dedifferentiation. Taking these findings together, we concluded that changes in the balance between the strengths of the PI3K/PKB(Akt) and the ERK and p38 MAPK pathways determines the VSMC phenotype. However, none of these studies, including those using VSMCs, revealed the cellular phenotype-dependent switching machinery of the IGF-induced signaling pathways.

Here we studied the VSMC phenotype-dependent actions of IGF-I by characterizing the IGF-I-induced signaling pathways. In differentiated VSMCs, SHP-2 preferentially associated with IRS-1 and inhibited the interaction between IRS-1 and Grb2/Sos, resulting in a blockade of the pathways from Ras to ERK and p38 MAPK. Therefore, in differentiated VSMCs, IGF-1 solely activates the PI3K/PKB(Akt) pathway, which plays a role in maintaining the differentiated phenotype. Conversely, the proliferation and migration of dedifferentiated VSMCs in response to IGF-I were because of an IGF-I-induced interaction between IRS-1 and Grb2/Sos, followed by the activation of Ras and its downstream kinases, ERK and p38 MAPK. This is the first report demonstrating that the cellular phenotype-dependent IRS-1/SHP-2 interaction functions as a switch for IGF-I signalings and distinct biological processes.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents and Antibodies—Signaling inhibitors (LY294002, wortmannin, PD98059, SB203580, and SB220025) were purchased from Calbiochem. Commercially available antibodies were purchased as follows: anti-ERK, anti-p38 MAPK, anti-PKB(Akt), anti-IGF-IR{beta}, anti-Sos, anti-Grb2, anti-SHP-2, anti-Gab1, and anti-Myc (9E10) antibodies (Santa Cruz Biotechnology); anti-Shc and anti-Grb2 antibodies (Transduction Laboratories); anti-BrdUrd antibody (DAKO); anti-HA (3F10) antibody (Roche Applied Science); anti-FLAG (M2) and anti-{alpha}-tubulin (DM 1A) antibodies (Sigma); anti-IRS-1 and anti-p85 PI3K, anti-phosphotyrosine (4G10), and anti-Ras (RAS10) antibodies (Upstate Biotechnology, Inc.); anti-IRS-1 Tyr(P)-895, Tyr(P)-1172, and Tyr(P)-1222 antibodies (BioSource); and anti-myosin heavy chain (MHC) SM2 antibody (Yamasa). Anti-SHPS-1 antibody was kindly provided by Dr. T. Matozaki (Gunma University). Anti-caldesmon (CaD) and anti-calponin (CN) antibodies (21) were also used.

VSMC Cultures—To obtain a large scale preparation of VSMCs, we modified our original method (20) as follows. Briefly, the aortae were quickly removed from ether-anesthetized 6-week-old Sprague-Dawley rats and were incubated for 30 min in the buffer containing 0.5 mg/ml collagenase (Yakult) and 0.5 mg/ml bovine serum albumin (BSA). Then the thin layers of adventitia and endothelium were carefully stripped off. The medial VSMC layers were minced well, and digested in Dulbecco's modified Eagle's medium containing 0.5 mg/ml collagenase, 0.5 mg/ml elastase (Sigma), and 5 mg/ml BSA for 60 min at 37 °C. Isolated VSMCs were filtered through a nylon membrane. The cells thus obtained were plated on laminin-coated plastic dishes and cultured in Dulbecco's modified Eagle's medium supplemented with 2 mg/ml BSA and other additions, as indicated. Passaged VSMCs were prepared from the medial VSMC layers of rat aortae as described previously (22). VSMCs passaged 2–5 times were used as dedifferentiated VSMCs.

Expression of SMC Marker Genes—The expression of h- and l-CaDs, CN, and MHC SM2 was quantified by reverse transcriptase-PCR normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase mRNA as described previously (20, 21).

Kinase Assays—The activities of endogenous kinases or exogenously expressed FLAG-ERK and FLAG-p38 MAPK were determined after immunoprecipitation with anti-ERK, anti-p38 MAPK, anti-PKB(Akt), or anti-FLAG antibodies. The kinase activities in the immunoprecipitates were assayed as described elsewhere (19, 23, 24). Assay conditions for FLAG-ERK and FLAG-p38 MAPK activities were as follows. VSMCs were cotransfected with the expression plasmid for FLAG-ERK2 or -p38 MAPK and control plasmid or the expression plasmids for {Delta}mSos, RasN17, RasV12, myc-SHP-2wt, myc-SHP-2DN, IRS-1-HAwt, IRS-1-HAF1172/F1222, or IRS-1-HAF895. After 24 h, they were stimulated with IGF-I (100 ng/ml) for 10 min. To confirm the expression of exogenous recombinant proteins, the cell extracts were analyzed by immunoblot. The rat IRS-1 cDNA was kindly provided by Dr. T. Kadowaki (University of Tokyo). Mutant IRS-1 cDNAs were constructed using PCR-associated mutagenesis, and their sequences were confirmed. The expression plasmids for RasN17 and RasV12 were kindly provided by Dr. T. Hirano (Osaka University Graduate School of Medicine).

Interactions between Signaling Molecules—VSMCs of both phenotypes under quiescent culture conditions were stimulated with the indicated amounts of IGF-I and lysed in buffer containing 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1% Nonidet P-40, 10% glycerol, 2 mM EDTA, 50 mM NaF, 1 mM vanadate, 10 mM {beta}-glycerophosphate, 50 µg/ml PMSF, 10 µg/ml leupeptin, and 5 µg/ml pepstatin, for 30 min at 0 °C. The interaction of signaling molecules because of exogenously expressed wild-type or mutant SHP-2 or IRS-1 was analyzed as follows. VSMCs were cotransfected with the expression plasmid for FLAG-Grb2 and control plasmid or the expression plasmid for myc-SHP-2wt or myc-SHP-2DN (Fig. 5A), or they were transfected with the expression plasmid for IRS-1-HAwt, IRS-1-HAF1172/F1222, or IRS-1-HAF895 (Fig. 5B). They were then stimulated with IGF-I (100 ng/ml) for 5 min. Equal amounts (400 µg of protein) of the cell extracts were incubated with the indicated antibodies for 6 h at 4 °C. The immune complexes were collected by incubation with protein A- or protein G-Sepharose beads for 2 h at 4 °C. Proteins in the immunoprecipitates were detected by immunoblot by using the indicated antibodies. Target proteins were detected with a SuperSignal chemiluminescent detection kit (Pierce) and quantified using the NIH Image program.



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 5.
Negative regulation of the IGF-I-induced interaction between IRS-1 and Grb2 by SHP-2. The effects of overexpressed SHP-2 derivatives (A) or IRS-1 derivatives (B) on the IRS-1/Grb2 interaction are shown. A, the extracts of VSMCs cultured under quiescent and IGF-I (100 ng/ml)-stimulated conditions, which were cotransfected with the expression plasmid for FLAG-Grb2 and control plasmid or the expression plasmid for myc-SHP-2wt or myc-SHP-2DN, were immunoprecipitated with an anti-FLAG antibody (Ab). myc-SHP-2wt or myc-SHP-2DN in the extracts (upper panel) and IRS-1 (middle panels) and FLAG-Grb2 (lower panel) in the immunoprecipitates (IP) were detected by immunoblot (IB). The right graph shows the quantification of the degree of IRS-1/Grb2 interaction; open and closed bars indicate the results in differentiated (D) and dedifferentiated (DD) VSMCs, respectively. Each value represents the mean ± S.D. of three independent experiments. B, VSMCs transfected with the expression plasmid for each of the HA-tagged IRS-I derivatives were cultured under the same conditions as described above. The cell extracts were immunoprecipitated with either anti-HA or anti-Grb2 antibody. HA-tagged IRS-1 derivatives and/or Grb2 in the respective immunoprecipitates were detected by immunoblot. These are representative results from three separate experiments.

 
Ras Activation Assay—The Ras activity was monitored using a Ras assay kit (Upstate Biotechnology, Inc.) according to the manufacturer's recommended procedures. In brief, the VSMC extracts were incubated with 15 µg of the Ras binding domain (RBD) of Raf-1-agarose beads for 30 min. Ras bound to Raf-1 RBD was detected by immunoblot using an anti-Ras antibody and then quantified.

PTPase Assay—VSMCs cultured under quiescent conditions were stimulated with IGF-I (100 ng/ml) or platelet-derived growth factor-BB (PDGF-BB) (20 ng/ml) for 5 min. The SHP-2 protein in the cell extracts was immunoprecipitated using an anti-SHP-2 antibody. The PTPase activities in the immunoprecipitates were assayed using tyrosine-phosphorylated Raytide as a substrate (25).

Cell Proliferation and Migration Assays—VSMCs of both phenotypes were cultured under quiescent conditions for 24 h and then stimulated with the indicated amounts of IGF-I. VSMC proliferation was determined by the incorporation of 5-bromo-2-deoxyuridine (BrdUrd) (20 µM) for 20 h. Incorporated BrdUrd was visualized by staining with an anti-BrdUrd antibody, followed by labeling with secondary antibodies conjugated with Alexa 546 (Molecular Probes) and Hoechst. The migration of differentiated VSMCs (four 1.5-mm diameter fields in each experiment) was monitored for 48 h by a cooled CCD camera (Roper Scientific, Tucson, AZ) mounted on an Olympus IX-70 microscope. The migration of dedifferentiated VSMCs was assayed by wound healing. Confluent cultures of dedifferentiated VSMCs were wounded with a single-edged razor blade. After stimulation with the indicated amounts of IGF-I for 48 h, the numbers of migrated cells were counted. The proliferation of dedifferentiated VSMCs transfected with wild-type or mutant HA-tagged IRS-1-expressing plasmids was assayed as follows. Dedifferentiated VSMCs (40–50% confluence) were transfected with the indicated expression plasmids and were cultured for 24 h. After serum starvation, they were cultured in the basal medium containing IGF-I (100 ng/ml) and BrdUrd for 20 h. The expression of HA-tagged IRS-I derivatives was visualized with anti-HA antibodies and Alexa 488 (Molecular Probes)-conjugated secondary antibodies. The migration of dedifferentiated VSMCs transfected with the indicated expression plasmids was monitored as described above. After stimulation with IGF-I (100 ng/ml) for 48 h, the expression of HA-tagged IRS-I derivatives was visualized as described above. The numbers of migrated cells and cells expressing each of HA-tagged IRS-1 derivatives were counted.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
VSMC Phenotype-dependent IGF-I Signaling Pathways—As demonstrated previously (19, 20), primary cultured VSMCs plated on laminin under IGF-I-stimulated conditions showed the differentiated phenotype, as indicated by a spindle-like cell shape, carbachol (CCH)-induced contractility (Fig. 1A), and high expression of SMC markers, such as h-CaD, CN, and MHC SM2, at the mRNA and protein levels (Fig. 1B). By contrast, passaged VSMCs, even when cultured under quiescent conditions, displayed a fibroblast-like shape change (Fig. 1A), loss of CCH-induced contractility (Fig. 1A), and down-regulation of SMC marker expression in addition to isoform conversion of CaD from the h-to l-form (Fig. 1B), indicating the dedifferentiated phenotype. By using both phenotypes of VSMCs, we first examined the dose-dependent response to IGF-I (Fig. 1, C–E). Consistent with our previous study (20), IGF-I (2 ng/ml) markedly activated PKB(Akt) in differentiated and dedifferentiated VSMCs, and its activation reached a maximum (more than 10-fold activation) at 20 ng/ml IGF-I (Fig. 1C). R3IGF-I, an IGF-I analog lacking affinity for IGF-binding proteins, showed a potency equivalent to IGF-I in activating PKB(Akt) in both phenotypes of VSMCs, at concentrations from 2 to 100 ng/ml (data not shown), suggesting that the IGF-I-induced signaling is IGF-binding protein-independent. The PKB(Akt) activation by IGF-I in both VSMC phenotypes was suppressed by LY294002 (10–30 µM) or wortmannin (10–30 nM), but not by PD98059 (20–30 µM) or SB203580 (10–20 µM), indicating that IGF-I induces the PKB(Akt) activation via PI3K. Notably, IGF-I, even at high concentrations (100 ng/ml), did not activate ERK or p38 MAPK in differentiated VSMCs, whereas it dose-dependently activated them in dedifferentiated VSMCs; their activations reached a maximum (more than 15- and 5-fold activations of ERK and p38 MAPK, respectively) at 20 ng/ml IGF-I (Fig. 1, D and E). In particular, the activation rates of PKB(Akt) and ERK by IGF-I were nearly identical, but p38 MAPK showed a slightly different IGF-I dose responsibility. The IGF-I-induced ERK activation was suppressed by PD98059 (20–30 µM) but not by SB203580 (10–20 µM), LY294002 (10–30 µM), or wortmannin (10–30 nM) (Fig. 1D). The p38 MAPK activation by IGF-I was only suppressed by SB203580 (10–20 µM, Fig. 1E) or SB220025 (10–20 µM, data not shown). These results indicate that IGF-I activates distinct VSMC phenotype-dependent signaling pathways.



View larger version (62K):
[in this window]
[in a new window]
  		FIG. 1.
Characterization of the different phenotypes of VSMCs. Cell morphology and CCH-induced contractility of differentiated (D) and dedifferentiated (DD) VSMCs are compared (A). Bar = 200 µm. The expression of SMC marker mRNAs was quantified by reverse transcriptase-PCR (B, upper panel). The numbers of PCR cycles and sizes of the PCR products are indicated. The expression of SMC marker proteins was shown by immunoblotting (IB) (B, lower panel). The PKB(Akt), ERK, and p38 MAPK activities triggered by IGF-I were assayed using their respective substrates: histone H2B (H2B) for PKB(Akt) (C); myelin basic protein (MBP) for ERK (D); and GST-ATF2 for p38 MAPK (E). VSMCs of both phenotypes cultured under quiescent conditions were stimulated with IGF-I with vehicle (-), PD98059 (P, 30 µM), SB203580 (S, 20 µM), wortmannin (W, 30 nM), or LY294002 (L, 30 µM) alone, or both PD98059 and SB203580 (P/S). PDGF-BB (20 ng/ml)-induced activations of ERK and p38 MAPK are positive controls for their activation in differentiated VSMCs. The left and right panels show the kinase activities and immunoblottings (IB). The open and closed bars indicate the kinase activities in differentiated and dedifferentiated VSMCs, respectively. The middle panels are the quantitative data of IGF-I dose dependences of these kinases. The values indicate the fold activation; the values under quiescent culture conditions were set at 1.0. Each value represents the mean ± S.D. of three independent experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

 
IGF-I-induced Interactions between Signaling Molecules— Signaling molecules, including IGF-IR, IRS-1, PI3K, Gab1, PK-B(Akt), Sos, Grb2, Ras, ERK, p38 MAPK, SHP-2, SHPS-1, and Shc, have been shown to be involved in IGF-I signaling in a variety of cells, including VSMCs (1, 3, 14, 16, 17). We compared the expression of these signaling molecules (Fig. 2). The IGF-IR{beta}, IRS-1, Shc, Gab1, SHPS-1, Sos, and Ras proteins were markedly up-regulated in dedifferentiated VSMCs compared with differentiated VSMCs, whereas ERK, p38 MAPK, p85 PI3K, PKB(Akt), SHP-2, and Grb2 proteins were equally expressed in both VSMC phenotypes. Thus, some signaling molecules show different expression profiles in different VSMC phenotypes.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 2.
Expression of signaling molecules in VSMCs. The whole-cell lysates from VSMCs, normalized by the protein content of ERK (21), were analyzed by immunoblot (A). The relative expression levels of each protein were quantified by densitometry and normalized to the levels in differentiated VSMCs, which was set at 1.0 (B). The open and closed bars indicate the relative content of each protein in differentiated (D) and dedifferentiated (DD) VSMCs, respectively. Each value represents the mean ± S.D. of three independent experiments.

 
To elucidate the molecular mechanism involved in VSMC phenotype-dependent IGF-I signalings, we examined the tyrosine phosphorylation and interactions of the signaling molecules. After IGF-I (2 and 100 ng/ml) stimulation, an anti-IGF-IR{beta} antibody specifically coimmunoprecipitated two tyrosine-phosphorylated proteins with molecular masses of 97 and 185 kDa in both VSMC phenotypes. We identified these proteins as IGF-IR{beta} (97 kDa) and IRS-1 (185 kDa) by using their respective antibodies (Fig. 3, A and D). An anti-IRS-1 antibody also coimmunoprecipitated IGF-IR{beta} in an IGF-I dose-dependent manner (data not shown). Tyrosine-phosphorylated IGF-IR{beta} and/or IRS-1 formed a complex with p85 PI3K but did not associate with Shc in either VSMC phenotype (Fig. 3, A and B, and D--F). We detected a stable complex of Grb2 and Sos in the anti-Grb2 (Fig. 3C) and anti-Sos (data not shown) immunoprecipitates of both VSMC phenotypes with or without IGF-I stimulation. Immunoblotting of the anti-Grb2 immunoprecipitates with anti-phosphotyrosine, anti-IRS-1, and anti-Sos antibodies showed that a complex of tyrosine-phosphorylated IRS-1 and Grb2/Sos formed in the dedifferentiated, but not in the differentiated, VSMCs (Fig. 3C), suggesting that the tripartite complex composed of IRS-1, Grb2, and Sos depends on the IGF-I-induced tyrosine phosphorylation of IRS-1. Immunoblotting of the anti-Sos immunoprecipitates with anti-IRS-1 and anti-Grb2 antibodies showed the same interactions in the IGF-I-stimulated dedifferentiated VSMCs (data not shown). The same tripartite complex was also detected in the anti-IRS-1 immunoprecipitates (Fig. 3B). Neither the IGF-I-induced tyrosine-phosphorylated Shc nor an Shc and IGF-IR{beta} or Grb2/Sos interaction was detected in either VSMC phenotype. As a control, PDGF-BB markedly induced tyrosine phosphorylation of Shc and an interaction between Shc and Grb2/Sos (Fig. 3F). The protein recognized by anti-phosphotyrosine antibody in the Shc immunoprecipitates from both phenotypes of VSMC was an IgG heavy chain, because anti-phosphotyrosine antibody cross-reacted with IgG heavy chain in rabbit antibodies (Fig. 3F). Because PDGF-BB or 18:1 lyso-phosphatidic acid potently induced the tyrosine phosphorylation of Shc in both VSMC phenotypes (Fig. 3F and data not shown), IGF-I signaling in VSMCs is Shc-independent. Thus, our results suggest that tyrosine-phosphorylated IRS-1 preferentially recruits the Grb2-Sos complex in dedifferentiated but not in differentiated VSMCs.



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 3.
IGF-I-stimulated interactions of signaling molecules. The extracts from VSMCs stimulated with IGF-I for 5 min were immunoprecipitated by using the indicated antibodies (Ab). The immunoprecipitates (IP) were analyzed by immunoblot (IB). Asterisks and double asterisks indicate tyrosine-phosphorylated IGF-IR{beta} and IRS-1, respectively. PDGF-BB-induced tyrosine phosphorylation of Shc and the cross-reactivity of anti-phosphotyrosine antibody (4G10) to rabbit antibody (IgG) are shown as controls (F). Arrows indicate the IgG heavy chain. These are representative results from three separate experiments. The interactions between IRS-1 or p85 PI3K and IGF-IR{beta} (D) and between p85 PI3K or Grb2 and IRS-1 (E) were quantified. The open and closed bars indicate the results in differentiated (D) and dedifferentiated (DD) VSMCs, respectively.

 
VSMC Phenotype-dependent Interaction of Tyrosine-phosphorylated IRS-1 and SHP-2—IRS-1 is phosphorylated on multiple tyrosine residues in response to IGFs. Among them, phosphorylated Tyr-895 of IRS-1 has been identified as a binding site for Grb2 (26). We analyzed the phosphorylation of IRS-1 Tyr-895 by using an anti-IRS-1 Tyr(P)-895 antibody. The IRS-1 Tyr-895 was markedly phosphorylated by IGF-I stimulation only in dedifferentiated VSMCs (Fig. 4A). This is consistent with the IGF-I-induced tripartite complex formation between tyrosine-phosphorylated IRS-1 and Grb2/Sos in dedifferentiated, but not in differentiated, VSMCs (Fig. 3). It is well documented that tyrosine-phosphorylated IRS-1 interacts with SHP-2, the ubiquitous PTPase containing the SH2 domain, leading to the positive or negative regulation of receptor tyrosine kinase-linked events (27–31). IRS-1 has two tyrosine residues for SHP-2 binding, Tyr-1172 and Tyr-1222 (32). We characterized the tyrosine phosphorylation of these SHP-2-binding sites using anti-IRS-1 Tyr(P)-1172 and Tyr(P)-1222 antibodies, respectively. In a preliminary experiment, the former antibody specifically recognized IRS-1 Tyr(P)-1172, but the latter did not recognize Tyr(P)-1222 (data not shown). We therefore analyzed the phosphorylated Tyr-1172 of IRS-1 in IGF-I-stimulated VSMCs. In response to IGF-I stimulation, IRS-1 Tyr-1172 was significantly phosphorylated in both VSMC phenotypes (Fig. 4A). We then examined the possible involvement of SHP-2 in the VSMC phenotype-dependent interaction between IRS-1 and Grb2/Sos. In both VSMC phenotypes under quiescent and IGF-I-stimulated conditions, almost all of the SHP-2 protein was extractable by nonionic detergents. Notably, IGF-I dose-dependently enhanced the PTPase activity of SHP-2 in differentiated VSMCs, whereas its effect was less significant in dedifferentiated ones. As a control, PDGF-BB enhanced the PTPase activity of SHP-2 in both the VSMC phenotypes (Fig. 4B). The PTPase activities might be mainly originated from the SHP-2 PTPase activity itself, because exogenously expressed Myc-tagged PTPase-dead (dominant-negative) SHP-2 (myc-SHP-2DN) (34) in IGF-I-stimulated differentiated VSMCs showed the low PTPase activity; 11.2 ± 1.0% of the wild-type SHP-2 (myc-SHP-2wt) PTPase activity (Fig. 4B). Thus, the IGF-I-induced PTPase activation is VSMC phenotype-specific. Consistent with this, an interaction between SHP-2 and tyrosine-phosphorylated IRS-1 was detected only in IGF-I-stimulated, differentiated VSMCs. The interaction reached a maximum 5 min after IGF-I stimulation, and decreased thereafter (Fig. 4C). This interaction process coincided well with the progressive changes in phosphorylation of Tyr-1172 (Fig. 4D). Thus, the extent of this interaction in differentiated VSMCs may depend on the phosphorylation of Tyr-1172 and possibly Tyr-1222 in IRS-1. No IRS-1/SHP-2 interaction was detected in dedifferentiated VSMCs, even when IRS-1 Tyr-1172 was phosphorylated by IGF-I stimulation (Fig. 4D), suggesting that an additional inhibitory mechanism of this interaction may exist in dedifferentiated VSMCs. No interactions between SHP-2 and other tyrosine-phosphorylated adaptor proteins, such as SHPS-1, Gab1, and Shc, were detected in either VSMC phenotype, even under the reported assay conditions (33, data not shown). Together, our results suggest that SHP-2 recruited to IRS-1 might rapidly dephosphorylate the IRS-1 Tyr-895 in differentiated VSMCs only.



View larger version (48K):
[in this window]
[in a new window]
  		FIG. 4.
VSMC phenotype-dependent IGF-I-induced IRS-1 phosphorylation, SHP-2 activation, and their interaction. IGF-I-induced tyrosine phosphorylation of IRS-1 in VSMCs was detected by immunoprecipitation (IP) followed by immunoblot (IB) using indicated anti-IRS-1 antibodies (A). The PTPase activity in the anti-SHP-2 or anti-Myc immunoprecipitates was assayed (B). The values indicate the fold activation; the values obtained in dedifferentiated VSMCs stimulated with IGF-I (2 ng/ml) were set at 1.0. The open and closed bars indicate the SHP-2 activities in differentiated (D) and dedifferentiated (DD) VSMCs, respectively (left panel). IGF-I-induced PTPase activities of myc-SHP-2wt (wt) and myc-SHP-2DN (DN) expressed in differentiated VSMCs were compared (right panel). The PTPase activity of myc-SHP-2wt was set at 100%. The SHP-2 protein contents are shown below each graph. Progressive changes in the tyrosine-phosphorylated IRS-1 and SHP-2 interaction were characterized (C). The extracts from VSMCs stimulated with IGF-I (100 ng/ml) were immunoprecipitated by using an anti-SHP-2 or anti-IRS-1 antibody. The target proteins in the immunoprecipitates were detected by immunoblot (left panels). Double asterisks indicate tyrosine-phosphorylated IRS-1. The tyrosine phosphorylation (pTyr) of IRS-I was quantified by densitometry (right graph). Open and closed bars indicate the results in differentiated and dedifferentiated VSMCs, respectively. These are representative results from three separate experiments, and each value represents the mean ± S.D. of three independent experiments. Progressive changes in the IGF-I (100 ng/ml)-induced tyrosine phosphorylation of Tyr-1172 of IRS-1 in both phenotypes of VSMC were characterized (D). Representative results from two separate experiments are shown.

 
Regulation of the IRS-1 and Grb2/Sos Interaction by SHP-2—We examined the effects of wild-type and dominant-negative SHP-2 on the IGF-I-induced interaction between IRS-1 and Grb2/Sos. The extracts from IGF-I-stimulated, differentiated, and dedifferentiated VSMCs cotransfected with expression plasmids for FLAG-tagged Grb2 (FLAG-Grb2) and myc-SHP-2wt or myc-SHP-2DN were immunoprecipitated with an anti-FLAG antibody, followed by immunoblotting with an anti-IRS-1 antibody (Fig. 5A). Overexpressed myc-SHP-2DN in differentiated VSMCs caused a new interaction between IRS-1 and Grb2, but myc-SHP-2wt did not. These results suggest that overexpressed SHP-2DN competes with endogenously activated SHP-2, leading to induction of the IRS-1 and Grb2/Sos interaction. In dedifferentiated VSMCs, overexpressed myc-SHP-2wt markedly suppressed the formation of this complex, but myc-SHP-2DN did not. This negative regulation in dedifferentiated VSMCs may be due to dephosphorylation of the IRS-1 Tyr(P)-895 by the overexpressed cytosolic SHP-2wt.

We further examined the IGF-I-induced interaction between Grb2 and HA-tagged wild-type IRS-I (HA-IRS-1wt) or its SHP-2-(Tyr-1172 and Tyr-1222 replaced with Phe; IRS-I-HAF1172/F1222) or Grb2 (Tyr-895 replaced with Phe; IRS-1-HAF895)-binding site mutants (Fig. 5B). In differentiated VSMCs, IRS-1-HAF1172/F1222 interacted with Grb2 in response to IGF-I stimulation, whereas IRS-1-HAwt and IRS-1-HAF895 did not. Conversely, IRS-1-HAwt and IRS-1-HAF1172/F1222 in dedifferentiated VSMCs formed a complex with Grb2 but IRS-1-HAF895 did not. Grb2 that was associated with IRS-1-HAwt or IRS-1-HAF1172/F1222 also formed a stable complex with Sos (data not shown), indicating a tripartite complex formation among these signaling molecules. Thus, SHP-2 negatively regulates the IRS-1 and Grb2/Sos interaction in a VSMC phenotype-dependent and IRS-1 phosphorylation site-specific manner.

Negative Regulation of ERK and p38 MAPK by SHP-2—To confirm the negative regulation of ERK and p38 MAPK by SHP-2, we cotransfected both phenotypes of VSMCs with expression plasmids for myc-SHP-2 (wt or DN) or IRS-1-HA (wt or indicated mutants) and FLAG-ERK or FLAG-p38 MAPK, and we assayed the ERK and p38 MAPK activities in the anti-FLAG immunoprecipitates (Fig. 6). IGF-I activated ERK and p38 MAPK in differentiated VSMCs expressing myc-SHP-2DN or IRS-1-HAF1172/F1222 but not in those expressing myc-SHP-2wt or IRS-1-HAwt. By contrast, IGF-I failed to activate ERK and p38 MAPK in dedifferentiated VSMCs expressing myc-SHP-2wt or IRS-1-HAF89, but barely affected either MAPK in dedifferentiated VSMCs expressing myc-SHP-2DN, IRS-1-HAwt, or IRS-1-HAF1172/F1222. Thus, the VSMC phenotype-dependent interaction between IRS-1 and Grb2/Sos, which is negatively regulated by SHP-2, is critical for the IGF-I-induced activation of both MAPKs.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 6.
The IRS-1/SHP-2 interaction functions as a switch to regulate the VSMC phenotype-dependent MAPK activation by IGF-I. The effects of overexpressed SHP-2 derivatives (A) and IRS-1 derivatives (B) on the IGF-I (100 ng/ml)-induced activation of ERK and p38 MAPK in VSMCs are shown. VSMCs were cotransfected with the expression plasmid for FLAG-ERK2 or FLAG-p38 MAPK and control plasmid or the expression plasmid for myc-SHP-2wt, myc-SHP-2DN, IRS-1-HAwt, IRS-1-HAF1172/F1222, or IRS-1-HAF895, and both MAPK activities in the anti-FLAG immunoprecipitates were determined. The values indicate the fold activation; the value under quiescent culture conditions was set at 1.0. Open and closed bars indicate the results in differentiated (D) and dedifferentiated (DD) VSMCs, respectively. Each value represents the mean ± S.D. of three independent experiments.

 
Ras as an Upstream Effector for the IGF-I-induced Activation of ERK and p38 MAPK—Although the Ras/Raf/MEK/ERK cascade is well known in various cell types (35), the pathway from Ras to p38 MAPK, however, remains unclear. Our present results suggest that Ras may be involved in the IGF-I-induced activation of both ERK and p38 MAPK in dedifferentiated VSMCs. We monitored the IGF-I-induced Ras activation with a Raf-1 binding assay. Consistent with the kinase activities (Fig. 1C) and interactions between signaling molecules (Fig. 3), IGF-I dose-dependently activated Ras in dedifferentiated, but not differentiated, VSMCs (Fig 7A). This activation was transient; Ras in dedifferentiated VSMCs was maximally activated at 5–10 min after IGF-I stimulation and the activation decreased thereafter. By contrast, IGF-I (2–100 ng/ml) maximally activated ERK and p38 MAPK for 10 min, and their activities remained high 4 h after stimulation (Fig. 7B). Thus, the transient activation of Ras induced by IGF-I led to rapidly rising and falling activities of both MAPKs, but the activities remained above the basal levels even 4 h after stimulation. To address the direct involvement of Ras in the IGF-I-induced MAPK activation in dedifferentiated VSMCs, we cotransfected dedifferentiated VSMCs with {Delta}mSos (36), RasN17, or RasV12 (37), and FLAG-ERK or FLAG-p38 MAPK, and we assayed for the ERK and p38 MAPK activities in the anti-FLAG immunoprecipitates. {Delta}mSos or RasN17 markedly suppressed the IGF-I-induced activation of both MAPKs; RasN17 inhibited both MAPK activities to less than basal levels, whereas {Delta}mSos did them to nearly the basal levels (Fig. 7C). In contrast, their activities were greatly enhanced by RasV12 without IGF-I stimulation (Fig. 7C). Thus, the Grb2/Sos/Ras cascade induced by IGF-I activates both ERK and p38 MAPK in dedifferentiated VSMCs.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 7.
Involvement of the Sos-Ras cascade in the IGF-I-induced activation of ERK and p38 MAPK in VSMCs. IGF-I-stimulated Ras activation in VSMCs was characterized (A). The Ras content in the Raf-1 RBD-bound fractions and the extracts (upper panels) was quantified (lower graph) by immunoblot. Progressive changes in IGF-I-stimulated ERK and p38 MAPK activation in dedifferentiated VSMCs are shown (B). Shaded and closed bars indicate the ERK and p38 MAPK activities, respectively. The values indicate the fold activation; the value under quiescent culture conditions was set at 1.0. Each value represents the mean ± S.D. of three independent experiments. The effects of {Delta}mSos or RasN17 and RasV12 on the IGF-I-induced activation of ERK and p38 MAPK in dedifferentiated VSMCs are shown (C). Dedifferentiated VSMCs were cotransfected with control plasmid or the indicated expression plasmids, and the expression plasmid for FLAG-ERK or -p38 MAPK and the ERK and p38 MAPK activities in the anti-FLAG immunoprecipitates were determined. The upper panels show the results of the kinase assays, and the middle and lower panels show the expression levels of the indicated proteins. Open and closed arrowheads indicate the endogenous Sos protein and the {Delta}mSos protein, respectively. These are representative results from three separate experiments. The bottom graphs indicate the quantification of kinase assays. The values indicate the fold activation; the values under quiescent culture conditions transfected with control plasmid were set at 1.0. Each value represents the mean ± S.D. of three independent experiments. D, differentiated; DD, dedifferentiated.

 
Relationships between IGF-I Signaling Pathways and Biological Actions of IGF-I on Distinct Phenotypes of VSMCs—To reveal the relationship between VSMC phenotype-dependent IGF-I signaling and its biological actions, we analyzed the IGF-I-induced cell proliferation and migration. Even under IGF-I-stimulated conditions, differentiated VSMCs never underwent cell proliferation, as monitored by BrdUrd incorporation (Fig. 8A) or migration (Fig. 8B), suggesting that IGF-I acts solely to maintain the differentiated phenotype but not as a mitogen or motogen. Conversely, IGF-I dose-dependently enhanced the proliferation and migration of dedifferentiated VSMCs (Fig. 8, A and B). Treatment with either PD98059 (30 µM) or SB203580 (20 µM) partially inhibited the BrdUrd incorporation and migration, but simultaneous treatment with both inhibitors completely suppressed them (Fig. 8, A and B), suggesting that these biological actions depend on the IGF-I-induced activation of ERK and p38 MAPK. We further analyzed the effects of the IGF-I-dependent interaction between IRS-I and Grb2/Sos on the BrdUrd incorporation and migration of dedifferentiated VSMCs by overexpressing IRS-1-HAwt, IRS-1-HAF895, or IRS-1-HAF1172/F1222. Dedifferentiated VSMCs expressing IRS-1-HAF895 showed markedly less BrdUrd incorporation and migration compared with those expressing either IRS-1-HAwt or IRS-1-HAF1172/F1222 (Fig. 9). These results indicate that the negative regulation of ERK and p38 MAPK by blockade of the IRS-1 and Grb2/Sos interaction results in inhibition of the proliferation and migration of dedifferentiated VSMCs.



View larger version (57K):
[in this window]
[in a new window]
  		FIG. 8.
VSMC phenotype-dependent biological actions of IGF-I. The effects of IGF-I on cell proliferation (A) and migration (B) are shown. VSMCs cultured under quiescent conditions were stimulated with IGF-I with vehicle (-), PD98059 (P, 30 µM), or SB203580 (S, 20 µM) alone, or both PD98059 and SB203580 (P/S). The percentages of BrdUrd-labeled cells in the cell population (200 cells in each experiment) (mean ± S.D. of three independent experiments) are shown (A). Photographs show the same fields of VSMC cultures before and after IGF-I (100 ng/ml) stimulation (B, upper panels). Arrows indicate fixed cell debris on the culture plate. Bar = 200 µm. The numbers of migrated VSMCs following IGF-I stimulation were counted (B, lower graph). Each value represents the mean ± S.D. of three independent experiments. D, differentiated; DD, dedifferentiated.

 



View larger version (54K):
[in this window]
[in a new window]
  		FIG. 9.
Effects of the IRS-1 and SHP-2 or Grb2 interaction on the IGF-I-induced proliferation and migration of dedifferentiated VSMCs. The effects of overexpressed HA-tagged IRS-1 derivatives on the proliferation as monitored by BrdUrd incorporation and the migration of dedifferentiated VSMCs are shown. HA-tagged IRS-1 derivatives are indicated at the top of each panel, respectively. Cells were stained with an anti-BrdUrd antibody, anti-HA antibody, and Hoechst. Merged images of BrdUrd (red) and HA-tagged IRS-1 derivatives (green) (left) and merged images of both of these plus nuclei (blue) (right) are shown (A). The values indicate the ratio of cells expressing each of the HA-tagged IRS-1 derivatives to those incorporating BrdUrd. Each value represents the mean ± S.D. of 6 different fields for each experiment (n = 3). In the cell migration assay, phase contrast micrographs of the cultures before (left) and 48 h after IGF-I stimulation (middle) and immunostaining of the HA-tagged IRS-1 derivatives in the same field (right) are shown (B). Orange and white lines indicate the edges of the VSMC cultures before and after IGF-I stimulation, respectively (right). The values indicate the ratio of migrated cells expressing each of the HA-tagged IRS-1 derivatives to total migrated cells. Each value represents the mean ± S.D. of 15 different fields for each experiment (n = 3). Bars = 200 µm. Ab, antibody.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Several studies have suggested that IGF-I is a potent mitogen and motogen for VSMCs, because IGF-I-induced activation of PI3K and/or MAPKs is involved in the proliferation and migration of VSMCs (12, 13). Conversely, we demonstrated by using our VSMC culture system that IGF-I plays a critical role in maintaining the differentiated phenotype of VSMCs via the PI3K/PKB(Akt), but not the ERK or p38 MAPK, pathway (19, 20). Here we demonstrate the distinct upstream signaling pathways, from IGF-IR to PI3K/PKB(Akt) and MAPKs, in different VSMC phenotypes and that the inconsistency regarding the distinct biological actions of IGF-I on VSMCs is because of the different VSMC phenotypes used. IGF-I potently activated ERK and p38 MAPK, via IRS-I-associated Grb2/Sos and Ras only in dedifferentiated VSMCs (Figs. 1 and 5, 6, 7), resulting in induction of the VSMC proliferation and migration (Figs. 8 and 9). Previous in vivo studies demonstrated that targeted overexpression of IGF-I in VSMCs (17) or IGF-I infusion into the circulatory system (18) enhances neointimal formation after vascular injury. Based on our present results, these in vivo observations might be explained by the idea that once VSMCs are primed by dedifferentiation stimuli such as vascular injury, IGF-I might further accelerate the proliferation and migration of dedifferentiated VSMCs via the signaling pathway shown in Fig. 10.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 10.
IGF-I plays a bifunctional role in the different VSMC phenotypes that is mediated through different signaling pathways. In differentiated (D) VSMCs, IGF-I induces the tyrosine phosphorylation of IGF-IR{beta} and IRS-1, but Grb2/Sos never associates with tyrosine-phosphorylated IRS-1, leading to inactivation of the ERK and p38 MAPK pathways. This negative regulation depends on SHP-2 associated with phosphorylated Tyr-1172 and Tyr-1222 of IRS-1, which dephosphorylates Tyr-895 of IRS-1. Tyrosine-phosphorylated IRS-1 also recruits p85 PI3K and then activates the PI3K/PKB(Akt) pathway, resulting in maintenance of the differentiated VSMC phenotype. In dedifferentiated (DD) VSMCs, the expression of some signaling molecules involved in the MAPK pathways is markedly up-regulated. In these cells, such IGF-I-induced negative regulation by SHP-2 is silent. Thus, phosphorylated Tyr-895 of IRS-1 recruits the Grb2/Sos and activates Ras followed by both MAPKs, leading to cell proliferation and migration.

 
In differentiated VSMCs, IRS-I-associated SHP-2 negatively regulates the activation of both ERK and p38 MAPK (Fig. 6). It has been reported that a variety of PTPases are involved in the positive and negative regulation of signal transduction via receptor tyrosine kinases (38). For instance, CD45 positively regulates the T-cell antigen receptor signaling in lymphocytes (39). In hematopoietic cell lines, SHP-1 negatively regulates mitogenic signals through the colony-stimulating factor 1 and stem-cell factor receptors (40). SHP-2 can modulate receptor tyrosine kinase-mediated signaling in a positive or negative manner. Positive regulation by SHP-2 has been reported in mitogenic signaling through the insulin receptor (27, 29). However, SHP-2 also negatively regulates insulin receptor-mediated mitogenic signaling (31) and gp130-dependent transcriptional activation (30). Our present study demonstrates that SHP-2 is critical for the VSMC phenotype-dependent regulation of IGF-I signaling; in differentiated VSMCs, an IRS-1/SHP-2 interaction enhances the PTPase activity of SHP-2 (Fig. 4) and suppresses the recruitment of Grb2/Sos to IRS-1 by the dephosphorylation of IRS-1 Tyr-895, resulting in inhibition of the activation of both MAPKs (Figs. 5 and 6). In contrast, SHP-2 remains inactive in IGF-I-stimulated dedifferentiated VSMCs (Fig. 4). The quiescence of SHP-2 PTPase activity in dedifferentiated VSMCs is a specific feature of the IGF-I signaling, given that PDGF-BB markedly enhanced the SHP-2 activity in dedifferentiated VSMCs (Fig. 4), and SHP-2 never interacted with signaling molecules such as IRS-1 (Fig. 4), SHPS-1, Gab1, or Shc (data not shown) in the IGF-I-stimulated dedifferentiated VSMCs. Maile and Clemmons (41) have reported that SHP-2 in passaged porcine VSMCs associates with SHPS-1, IGF-IR{beta}, and IRS-1 in response to IGF-I stimulation, and these interactions depend on integrin-associated protein. It is reasonable to consider that the pathway via SHPS-1 might not function in differentiated VSMCs, given that no integrin-associated protein expression is detected in differentiated VSMCs in vivo (42). Our results using dedifferentiated VSMCs also showed this pathway to be silent. Presently, the reasons for this discrepancy remain unknown. The IRS-1 Tyr-1172 was significantly phosphorylated in IGF-I-stimulated dedifferentiated VSMCs. However, the IRS-1/SHP-2 interaction is not detected in dedifferentiated VSMCs despite such a tyrosine phosphorylation state of IRS-1 (Fig. 4). The IGF-I-induced interaction between IRS-1 and Grb2/Sos and the activation of ERK and p38 MAPK are markedly inhibited in dedifferentiated VSMCs overexpressing SHP-2wt (Figs. 5 and 6). These results suggest that in dedifferentiated VSMCs, the function of SHP-2 would be blocked by interacting with other tyrosine-phosphorylated proteins. Therefore, excess SHP-2wt might overcome such trapping of endogenous SHP-2 or dephosphorylate IRS-1 Tyr-895, resulting in blockade of the interaction between IRS-1 and Grb2/Sos.

Ras is a key transducer of mitogenic signaling in many cell types, including VSMCs, in vitro and in vivo. It is well documented that Ras activates ERK in a variety of cells, whereas stress-activated protein kinases, including p38 MAPK, are poorly activated by the Ras-coupled cascade (35). We now demonstrate that the activation of Ras functions as an upstream effector for both ERK and p38 MAPK in IGF-I-stimulated dedifferentiated VSMCs (Fig. 7). However, unlike the ERK pathway mediated through Ras/Raf/MEK, the p38 MAPK pathway might be indirectly affected by Ras, because IGF-I dose-responsive activation rates of both MAPKs were slightly different (Fig. 1, D and E). It has been reported that in some cell lines, including myoblast lines PKB(Akt), phosphorylate Raf, leading to suppression of the Ras/Raf/MEK/ERK axis (43). In our present study by using both phenotypes of VSMCs, treatment with PI3K inhibitor never increased the ERK activation by IGF-I (Fig. 1), suggesting that the PKB(Akt)-mediated negative regulation of the ERK pathway may not be involved.

Our present study provides a novel insight into the signal transduction in VSMCs and into the pharmacological approaches that might be applicable for preventing vascular disorders such as atherosclerosis and restenosis. As described in the Introduction, IGF-I signal affects the mutually exclusive biological actions, such as proliferation and differentiation of hematopoietic cells, adipocytes, myoblasts, and osteoblasts. In these cells, the signaling pathways analogous to those of VSMCs (Fig. 10) may be involved in the distinct biological actions of IGF-I. In our preliminary experiments, we have identified the similar pathways regulating the IGF-I-induced proliferation and differentiation of myogenic cells.2 Thus, the IGF-I-induced pathways demonstrated here appear to represent a novel mechanism regulating the discriminating signals involved in cell proliferation and differentiation, not just in VSMCs, but in other cells as well.


   FOOTNOTES
 
* This work was supported by Grant-in-aid for Scientific Research 15GS0312 from the Ministry of Education, Science, Sports and Culture of Japan (to K. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Tel.: 81-6-6879-3680; Fax: 81-6-6879-3689; E-mail: sobue{at}nbiochem.med.osaka-u.ac.jp.

1 The abbreviations used are: IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; ERK, extracellular signal-regulated kinase; IRS-1, insulin receptor substrate-1; PKB(Akt), protein kinase B; VSMCs, vascular smooth muscle cells; MHC, myosin heavy chain; CaD, caldesmon; CN, calponin; BSA, bovine serum albumin; RBD, Ras-binding-domain; PTPase, protein-tyrosine phosphatase; PDGF-BB, platelet-derived growth factor-BB; BrdUrd, 5-bromo-2-deoxyuridine; CCH, carbachol; wt, wild type; DN, dominant negative; HA, hemagglutinin. Back

2 K. Hayashi, K. Shibata, T. Morita, K. Iwasaki, M. Watanabe, and K. Sobue, manuscript in preparation. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T., Jr. (1995) Endocr. Rev. 16, 143-163[Abstract/Free Full Text]
  2. Yenush, L., and White, M. F. (1997) BioEssays 19, 491-500[CrossRef][Medline] [Order article via Infotrieve]
  3. Rozakis-Adcock, M., McGlade, J., Mbamalu, G., Pelicci, G., Daly, R., Li, W., Batzer, A., Thomas, S., Brugge, J., Pelicci, P. G., Schlessinger, J., and Pawson, T. (1992) Nature 360, 689-692[CrossRef][Medline] [Order article via Infotrieve]
  4. Oldham, S., and Hafen, E. (2003) Trends Cell Biol. 13, 79-85[CrossRef][Medline] [Order article via Infotrieve]
  5. Giorgetti, S., Pelicci, P. G., Pelicci, G., and Van Obberghen, E. (1994) Eur. J. Biochem. 223, 195-202[Medline] [Order article via Infotrieve]
  6. Gu, H., and Neel, B. G. (2003) Trends Cell Biol. 13, 122-130[CrossRef][Medline] [Order article via Infotrieve]
  7. Rocchi, S., Tartare-Deckert, S., Murdaca, J., Holgado-Madruga, M., Wong, A. J., and Van Obberghen, E. (1998) Mol. Endocrinol. 12, 914-923[Abstract/Free Full Text]
  8. Coolican, S. A., Samuel, D. S., Ewton, D. Z., McWade, F. J., and Florini, J. R. (1997) J. Biol. Chem. 272, 6653-6662[Abstract/Free Full Text]
  9. Valentinis, B., Romano, G., Peruzzi, F., Morrione, A., Prisco, M., Soddu, S., Cristofanelli, B., Sacchi, A., and Baserga, R. (1999) J. Biol. Chem. 274, 12423-23430[Abstract/Free Full Text]
  10. Boney, C. M, Smith, R. M., and Gruppuso, P. A. (1998) Endocrinology 139, 1638-1644[Abstract/Free Full Text]
  11. Yeh, L. C., Adamo, M. L., Olson, M. S., and Lee, J. C. (1997) Endocrinology 138, 4181-4190[Abstract/Free Full Text]
  12. Bornfeldt, K. E., Rainco, E. W., Nakano, T., Groves, L. M., Krebs, E., and Ross, R. (1993) J. Clin. Investig. 93, 1266-1274[CrossRef]
  13. Bayes-Genis, A., Conover, C. A., and Schwartz, R. S. (2000) Circ. Res. 86, 125-130[Abstract/Free Full Text]
  14. Avena, R., Mitchell, M. E., Carmody, B., Arora, S., Neville, R. F., and Sidaway, A. N. (1999) Am. J. Surg. 178, 156-161[CrossRef][Medline] [Order article via Infotrieve]
  15. Simons, M., Ariyoshi, H., Salzman, E. W., and Rosenberg, R. D. (1995) Am. J. Physiol. 268, C856-C868
  16. Du, J., and Delafontaine, P. (1995) Circ. Res. 76, 963-972[Abstract/Free Full Text]
  17. Zhu, B., Zhao, G., Witte, D. P., Hui, D. Y., and Fagin, J. A. (2001) Endocrinology 142, 3598-3606[Abstract/Free Full Text]
  18. Chen, Y., Capron, L., Magnusson, J. O., Wallby, L. A., and Arnqvist, H. J. (1998) Growth Horm. IGF Res. 8, 299-303[CrossRef][Medline] [Order article via Infotrieve]
  19. Hayashi, K., Takahashi, M., Kimura, K., Nishida, W., Saga, H., and Sobue, K. (1999) J. Cell Biol. 145, 727-740[Abstract/Free Full Text]
  20. Hayashi, K., Takahashi, M., Nishida, W., Yoshida, K., Ohkawa, Y., Kitabatake, A., Aoki, J., Arai, H., and Sobue, K. (2001) Circ. Res. 89, 251-258[Abstract/Free Full Text]
  21. Takahashi, M., Hayashi, K., Yoshida, K., Ohkawa, Y., Komurasaki, T., Kitabatake, A., Ogawa, A., Nishida, W., Yano, M., Monden, M., and Sobue, K. (2003) Circulation 108, 2524-2529[Abstract/Free Full Text]
  22. Pukac, L., Huangpu, J., and Karnovsky, M. J. (1998) Exp. Cell Res. 242, 548-560[CrossRef][Medline] [Order article via Infotrieve]
  23. Hayashi, K., Saga, H., Chimori, Y., Kimura, K., Yamanaka, Y., and Sobue, K. (1998) J. Biol. Chem. 273, 28860-28867[Abstract/Free Full Text]
  24. Yoshida, K., Nishida, W., Hayashi, K., Ohkawa, Y., Ogawa, A., Aoki, J., Arai, H., and Sobue, K. (2003) Circulation 108, 1746-1752[Abstract/Free Full Text]
  25. Huang, Q., Lerner-Marmarosh, N., Che, W., Ohta, S., Osawa, M., Yoshizumi, M., Glassman, M., Yan, C., Berk, B. C., and Abe, J. (2002) J. Biol. Chem. 277, 29330-29341[Abstract/Free Full Text]
  26. Ward, C. W., Gough, K. H., Rashke, M., Wan, S. S., Tribbick, G., and Wang, J. (1996) J. Biol. Chem. 271, 5603-5609[Abstract/Free Full Text]
  27. Noguchi, T., Matozaki, T., Horita, K., Fujioka, Y., and Kasuga, M. (1994) Mol. Cell. Biol. 14, 6674-6682[Abstract/Free Full Text]
  28. Xiao, S., Rose, D. W., Sasaoka, T., Maegawa, H., Burke, T. R., Jr., Roller, P. P., Shoelson, S. E., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 21244-21248[Abstract/Free Full Text]
  29. Milarski, K. L., and Saltiel, A. R. (1994) J. Biol. Chem. 269, 21239-21243[Abstract/Free Full Text]
  30. Symes, A., Stahl, N., Reeves, S. A., Farruggella, T., Servidei, T., Gearan, T., Yancopoulos, G. D., and Fink, J. S. (1997) Curr. Biol. 7, 697-700[CrossRef][Medline] [Order article via Infotrieve]
  31. Myers, M. G., Jr., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., and White, M. F. (1998) J. Biol. Chem. 273, 26908-26914[Abstract/Free Full Text]
  32. Case, R. D., Piccione, E., Wolf, G., Benett, A. M., Lechleider, R. J., Neel, B. G., and Shoelson, S. E. (1994) J. Biol. Chem. 269, 10467-10474[Abstract/Free Full Text]
  33. Maile, L. A., and Clemmons, D. R. (2002) J. Biol. Chem. 277, 8955-8960[Abstract/Free Full Text]
  34. Frearson, J. A., and Alexander, D. R. (1998) J. Exp. Med. 187, 1417-1426[Abstract/Free Full Text]
  35. Johnson, G. L., and Lapadat, R. (2002) Science 298, 1911-1912[Abstract/Free Full Text]
  36. Sakaue, M., Bowtell, D., and Kasuga, M. (1995) Mol. Cell. Biol. 15, 379-388[Abstract]
  37. Matsumura, I., Nakajima, K., Wakao, H., Hattori, S., Hashimoto, K., Sugahara, H., Kato, T., Miyazaki, H., Hirano, T., and Kanakura, Y. (1998) Mol. Cell. Biol. 18, 4282-4290[Abstract/Free Full Text]
  38. Ostman, A., and Bohmer, F.-D. (2001) Trends Cell Biol. 11, 258-266[CrossRef][Medline] [Order article via Infotrieve]
  39. Thomas, M. L., and Brown, E. J. (1999) Immunol. Today 20, 406-411[CrossRef][Medline] [Order article via Infotrieve]
  40. Chen, H. E., Chang, S., Trub, T., and, Neel, B. G. (1996) Mol. Cell. Biol. 16, 3685-3697[Abstract]
  41. Maile, L. A., and Clemmons, D. R. (2003) Circ. Res. 93, 925-931[Abstract/Free Full Text]
  42. Sajid, M., Hu, Z., Guo, H., Li, H., and Stouffer, G. A. (2001) J. Investig. Med. 49, 398-406[Medline] [Order article via Infotrieve]
  43. Zimmermann, S., and Moelling, K. (1999) Science 286, 1741-1744[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
H. Alam, J. Weck, E. Maizels, Y. Park, E. J. Lee, M. Ashcroft, and M. Hunzicker-Dunn
Role of the Phosphatidylinositol-3-Kinase and Extracellular Regulated Kinase Pathways in the Induction of Hypoxia-Inducible Factor (HIF)-1 Activity and the HIF-1 Target Vascular Endothelial Growth Factor in Ovarian Granulosa Cells in Response to Follicle-Stimulating Hormone
Endocrinology, February 1, 2009; 150(2): 915 - 928.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. Morrow, S. Guha, C. Sweeney, Y. Birney, T. Walshe, C. O'Brien, D. Walls, E. M. Redmond, and P. A. Cahill
Notch and Vascular Smooth Muscle Cell Phenotype
Circ. Res., December 5, 2008; 103(12): 1370 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. A. Martin, B. L. Merenick, M. Ding, K. M. Fetalvero, E. M. Rzucidlo, C. D. Kozul, D. J. Brown, H. Y. Chiu, M. Shyu, B. L. Drapeau, et al.
Rapamycin Promotes Vascular Smooth Muscle Cell Differentiation through Insulin Receptor Substrate-1/Phosphatidylinositol 3-Kinase/Akt2 Feedback Signaling
J. Biol. Chem., December 7, 2007; 282(49): 36112 - 36120.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
E. Hirsch, C. Costa, and E. Ciraolo
Phosphoinositide 3-kinases as a common platform for multi-hormone signaling
J. Endocrinol., August 1, 2007; 194(2): 243 - 256.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. A. Maile, B. E. Capps, Y. Ling, G. Xi, and D. R. Clemmons
Hyperglycemia Alters the Responsiveness of Smooth Muscle Cells to Insulin-Like Growth Factor-I
Endocrinology, May 1, 2007; 148(5): 2435 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. M. Risinger Jr., T. S. Hunt, D. L. Updike, E. C. Bullen, and E. W. Howard
Matrix Metalloproteinase-2 Expression by Vascular Smooth Muscle Cells Is Mediated by Both Stimulatory and Inhibitory Signals in Response to Growth Factors
J. Biol. Chem., September 8, 2006; 281(36): 25915 - 25925.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Nigro, N. Osman, A. M. Dart, and P. J. Little
Insulin Resistance and Atherosclerosis
Endocr. Rev., May 1, 2006; 27(3): 242 - 259.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Kwon, Y. Ling, L. A. Maile, J. Badley-Clark, and D. R. Clemmons
Recruitment of the Tyrosine Phosphatase Src Homology 2 Domain Tyrosine Phosphatase-2 to the p85 Subunit of Phosphatidylinositol-3 (PI-3) Kinase Is Required for Insulin-Like Growth Factor-I-Dependent PI-3 Kinase Activation in Smooth Muscle Cells
Endocrinology, March 1, 2006; 147(3): 1458 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A. W Stoker
Protein tyrosine phosphatases and signalling
J. Endocrinol., April 1, 2005; 185(1): 19 - 33.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/39/40807    most recent
M405100200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, K.
Right arrow Articles by Sobue, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, K.
Right arrow Articles by Sobue, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement